Targeted Therapy for Skeletal Muscle Fibrosis: Regulation of Myostatin, TGF-β, MMP, and TIMP to Maintain Extracellular Matrix Homeostasis
- PMID: 40260056
- PMCID: PMC12011048
- DOI: 10.2147/BTT.S508221
Targeted Therapy for Skeletal Muscle Fibrosis: Regulation of Myostatin, TGF-β, MMP, and TIMP to Maintain Extracellular Matrix Homeostasis
Abstract
Muscle fibrosis, defined by the excessive deposition of extracellular matrix (ECM) components, is a key pathological process that hinders muscle regeneration following injury. Despite muscle's inherent regenerative potential, severe or chronic injuries often result in fibrosis, which compromises muscle function and impedes healing. This review explores a range of therapeutic strategies aimed at modulating the molecular pathways involved in muscle fibrosis, with a focus on the inhibition of myostatin and transforming growth factor-β (TGF-β), as well as the regulation of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs). Some therapy modalities, including physiotherapy and exercise therapy, which are commonly used, have demonstrated the ability to regulate extracellular matrix (ECM) components and promote muscle repair. In addition, the use of TGF-β inhibitors, herbal plants, and other biochemically relevant compounds, holds promise in controlling fibrosis by targeting key signaling pathways that drive ECM accumulation as well as having anti-fibrotic and anti-inflammatory properties. Regenerative medicine, including therapies using stem cell, secretome, and platelet-rich plasma (PRP), have also been used as single or adjuvant treatment for muscle fibrosis, and represents a novel and minimally invasive approach. Although these therapeutic strategies show considerable promise, translating preclinical findings to clinical practice remains challenging owing to variability in patient responses and the complexity of human muscle injuries. In conclusion, a multifaceted approach targeting ECM regulation, either as single treatment or combined treatment, offers a promising avenue for the treatment of muscle fibrosis.
Keywords: MMP; TGF-β; TIMP; extracellular matrix; muscle fibrosis; myostatin.
© 2025 Dewi et al.
Conflict of interest statement
The authors report no conflicts of interest in this work.
Figures
Similar articles
-
Control of extracellular matrix homeostasis of normal cartilage by a TGFbeta autocrine pathway. Validation of flow cytometry as a tool to study chondrocyte metabolism in vitro.Osteoarthritis Cartilage. 2002 Mar;10(3):188-98. doi: 10.1053/joca.2001.0492. Osteoarthritis Cartilage. 2002. PMID: 11869079
-
Targeting TGF-β Mediated SMAD Signaling for the Prevention of Fibrosis.Front Pharmacol. 2017 Jul 14;8:461. doi: 10.3389/fphar.2017.00461. eCollection 2017. Front Pharmacol. 2017. PMID: 28769795 Free PMC article. Review.
-
Ureic clearance granule, alleviates renal dysfunction and tubulointerstitial fibrosis by promoting extracellular matrix degradation in renal failure rats, compared with enalapril.J Ethnopharmacol. 2014 Sep 29;155(3):1541-52. doi: 10.1016/j.jep.2014.07.048. Epub 2014 Aug 1. J Ethnopharmacol. 2014. PMID: 25087615
-
TGF-β1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells.BMC Cancer. 2012 Jan 19;12:26. doi: 10.1186/1471-2407-12-26. BMC Cancer. 2012. PMID: 22260435 Free PMC article.
-
Therapeutic strategies for preventing skeletal muscle fibrosis after injury.Front Pharmacol. 2015 Apr 21;6:87. doi: 10.3389/fphar.2015.00087. eCollection 2015. Front Pharmacol. 2015. PMID: 25954202 Free PMC article. Review.
References
-
- Meiliana A, Dewi NM, Defi IR, Rosdianto AM, Qiantori AA, Wijaya A. Sarcopenic obesity: the underlying molecular pathophysiology and prospect therapies. Indones Biomed J. 2024;16(4):292–308. doi:10.18585/inabj.v16i4.3176 - DOI
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous